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ABSTRACT 
Breast cancer (BC) is a heterogeneous disease featuring distinct histological, molecular 
and clinical phenotypes. Although traditional classification systems utilising 
clinicopathological and few molecular markers are well-established and validated they 
remain insufficient to reflect the diverse biological and clinical heterogeneity of BC. 
Advancements in high-throughput molecular techniques and bioinformatics have 
contributed to the improved understanding of BC biology, refinement of molecular 
taxonomies and the development of novel prognostic and predictive molecular assays. 
Application of such technologies is already underway, and is expected to change the way 
we manage BC. Despite the enormous amount of work that has been carried out to develop 
and refine BC molecular prognostic and predictive assays, molecular testing is still in 
evolution. Pathologists should be aware of the new technology and be ready for the 
challenge. In this review, we provide an update on the application of molecular techniques 
with regard to BC diagnosis, prognosis and outcome prediction. Current contribution of the 
emerging technology to our understanding of BC is also highlighted.  
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INTRODUCTION 
Historically breast cancer (BC) was classified based on clinicopathological features mainly 
tumour stage, and grade. Other morphological features such as histological type, 
proliferation status and lymphovascular invasion are also recognised as important 
morphological prognostic variables that reflect tumour biology (1, 2). Over time, 
knowledge about BC biology has significantly increased and led to the understanding that 
BC represents a heterogeneous group of tumours and that tumour behaviour and response 
to therapy is determined by the underlying biological features. The expression of oestrogen 
receptor (ER), progesterone receptor (PgR) and the human epidermal growth factor 
receptor 2 (HER2) that were originally identified as predictive of response to systemic 
therapy are now recognised to be the main determinants of BC biology and can be used to 
refine BC molecular and prognostic taxonomy. More recently, molecular data arising from 
a variety of high throughput techniques have been used to refine BC stratification and 
develop prognostic and predictive classification with the aim of individualised therapy.  
Although molecular taxonomy of BC based on gene expression profiling, proteomics, 
DNA copy number alteration and chromosomal changes, mutation status, methylation and 
microRNAs has been expanding for many years and has increased our knowledge of BC 
biology, its clinical application remains limited. The introduction of next generation 
sequencing (NGS) or massively parallel sequencing (3) appears to have opened new 
avenues for decoding BC molecular complexity, refine molecular classification and 
identify new therapeutic targets. These molecular techniques hold promise for improving 
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diagnosis, prediction of outcome and behaviour, and in aiding selection of therapies for 
individual patients (4). However, its clinical utility is still under investigation (5). 
Pathologists are currently using conventional and novel molecular techniques on routine 
practice to help diagnosis of morphologically challenging entities, to assess the expression 
of hormone receptors and HER2 status on every BC and help oncologists to refine the 
prognostic stratification of BC and complement the morphological variables with 
molecular biomarkers. Although immunohistochemistry (IHC) remains the most 
commonly used conventional molecular technique, other techniques are increasingly used 
in routine practice including in situ hybridisation (ISH), RT-PCR, and in some centres NGS 
and expression microarrays. In the research setting, several other molecular techniques are 
used inc luding compara t ive genomic hybr id isa t ion (CGH), expanded 
immunohistochemistry with tissue microarrays and proteomics. In this review, the main 
applications of molecular techniques on BC are highlighted with emphasis on the practical 
applications which can be generally divided into three main categories; diagnosis, 
molecular prognostic and predictive taxonomies.   
Using molecular biomarkers in the diagnosis of breast lesions 
In addition to prognosis and treatment response prediction, molecular biomarkers are 
frequently used in the diagnosis of challenging breast lesions; to differentiate between 
benign and malignant entities, in situ and invasive tumours, subtyping of certain lesions 
and determination of the tissue of origin of less differentiated malignant tumours. The most 
frequent technique utilising in this aspect is IHC often using a panel of biomarkers (6, 7). 
  
IHC plays a useful role in diagnosing spindle cell lesions, identification of myoepithelial 
cells, differentiate between ductal and lobular phenotype and between hyperplastic 
epithelial proliferative process from neoplastic clonal epithelial proliferation and in the 
classification of papillary lesions. Cytokeratins can be used to detect small nodal 
metastases or subtle invasive carcinomas such as invasive lobular carcinomas. IHC also is 
helpful in recognising metastases to the breast and mammary carcinomas metastasising to 
extramammary tissues. Different antibodies are useful for different tumours: PAX8 and 
WT1 for ovarian carcinoma; TTF1 for thyroid and pulmonary adenocarcinoma; melan-A, 
HMB45 and S100 for melanoma; and lymphoid markers for lymphoma. Specific genetic 
translocations are also helpful for diagnosis of certain breast lesions (see below) and for 
exclusion of specific soft tissue tumours when identified on a biopsy as a component of 
other mammary-specific lesions; for instance pure stromal component of a malignant 
phyllodes tumour to be differentiated from other soft tissue sarcomas that may have 
different management strategies (8).   
Companion diagnostics in breast cancer 
The ability to predict an individual’s response to a specific therapy is the main aim in 
modern precision medicine. A molecular diagnostic tool in the field of cancer therapy was 
first used in the 1970s to predict response of BC to the selective oestrogen receptor 
modulator, tamoxifen based on the expression of ER (9). Currently, several targeted cancer 
therapies are utilised in standard oncological care and this field is expanding. As a result, 
the concept of “companion diagnostics” has emerged which can be defined as a diagnostic 
test used as a companion to a therapeutic drug to determine its applicability to a specific 
patient. Currently, the US Food and Drug Administration (FDA)-approved companion 
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diagnostics are utilised in BC tests for the presence of HER2 protein overexpression or 
gene amplification. Despite not considered companion diagnostics by the FDA, ER and 
PgR testing is mandatory for effective hormone therapy decision making and can be 
considered as companion diagnostics in BC. Although prognostic multigene assays are not 
companion diagnostics per se, as they are not linked to a particular drug, they can result in 
changes in clinical decisions and treatment course based on their outcome predictions 
(Table 1). 
HORMONE RECEPTOR TESTING: Hormone receptor status is determined by the tumour 
cells’ expression of nuclear receptors for oestrogen (ER) and progesterone (PgR). 
Biochemical ligand-binding assays were initially used to detect ER and PgR, but they 
required fresh tissue and were technically challenging and therefore IHC assays have 
become routine. Different scoring methods are in use for determining the level of 
expression but the most widely used systems are the Allred scoring and the histochemical 
score (H-score) methods which both assess the proportion and intensity of staining that are 
summed to give an overall score. However, the currently agreed cut-off of positivity of ER 
and PgR for management purpose relies on proportion scoring and is 1% (10). Patients 
with BC showing any nuclear expression of hormone receptor in invasive tumour cells 
above the cut-off are likely to respond to hormone therapy and are therefore potential 
candidates for this therapy. However, for a diagnostic purpose, i.e. determination of a 
mammary origin of a metastatic carcinoma, a more stringent definition of positivity is 
often used based on the pathologist’s discretion.  Although current guidelines indicate that 
IHC is used for determination of hormone receptor status (10) in BC, ER and PgR are 
component genes of some multigene assays including Oncotype DX. Information 
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regarding hormone receptor status using these assays can be used as an additional quality 
measures for assessment methods. Discrepancy of results should trigger a reflex test.    
HER2 TESTING: HER2 is overexpressed in 12% to 20% of BC most often because of 
HER2 gene amplification. Because of its predictive value, guideline recommendations for 
its assessment (11) and their updated versions (12, 13) have been published to provide 
guidance on HER2 testing in BC.  Key aspects of these guidelines include a 
recommendation that all BC be tested for HER2 using IHC and subsequently with ISH in 
borderline positive IHC cases using a validated test. It should be recognised that both IHC 
and ISH represent an attempt to convert a continuous biological variable into a dichotomous 
category and borderline or equivocal cases exist and a reflex test is recommended to reduce 
the proportion of these cases. The use of the updated definition of positivity of HER2 has 
reduced the proportion of these borderline cases (12, 13).  
Ki67 PROLIFERATION INDEX: The Ki67 proliferation index has been investigated as a 
BC prognostic and predictive factor in various settings (14). Ki67 is assessed in routine 
practice using IHC however, its analytic validity remains a matter of debate and formal 
inter-and intra-laboratory standardisation hampers its use in routine practice for 
management decision (15). Ki67 can be used in routine practice to i) determine the 
proliferation status in poorly fixed specimens, or 2) stratify grade 2 tumours into two 
prognostically distinct classes (16) akin to the molecular grade index (17). Ki67 is also used 
a component of some prognostic tools (18) however; the published 2016 American Society 
of Clinical Oncology (ASCO) clinical practice guideline on BC (15) recommends that Ki67 
labelling index determined by IHC should not be used to guide choice on adjuvant 
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chemotherapy with intermediate quality of evidence base and moderate strength of 
recommendation. 
GENETIC TESTS AND DIAGNOSIS: Some diagnostic microarray-based gene expression 
tests were developed for identification of cancer tissue of origin. These include the 
Pathwork Tissue of Origin Test that was developed using a 2000-gene classification model 
for identification of tumour tissue of origin with an overall accuracy in identifying the 
primary site of poorly differentiated tumours up to 90% (19) and the THEROS Cancer 
TYPE ID® which is a RT-PCR-based test using 92 genes and FFPE samples (20). 
Importantly, some special type mammary carcinomas show specific translocations which 
characterise these tumours and can be used as diagnostic adjunct. Secretory carcinoma of 
the breast is characterised by a balanced translocation of genetic material between 
chromosomes 12 and 15 (t(12;15)) creating a new gene in which the 5' region of ETV6 is 
fused to the 3' region of NTRK3 producing ETV6-NTRK3 fusion gene (57). 
Mucoepidermoid carcinoma which is a rare type of metaplastic BC is characterised by a 
translocation between chromosome 11 and 19 (t(11;19)(q21;p13)) creating a novel fusion 
product between mucoepidermoid carcinoma translocated 1 (MECT1) and Mastermind-
like gene family (MAML2); MECT1-MAML2 fusion gene (58). Adenoid cystic 
carcinomas as well as cylindroma show a specific translocation t(6;9)(q22-23;p23-24) 
creating MYB-NFIB fusion gene (59).  In a study of breast adenoid cystic carcinoma 
mixed with a high grade triple negative BC components, the MYB-NFIB fusion gene was 
detected in both tumour subtypes and it was postulated that the progression from adenoid 
cystic carcinoma to high-grade triple-negative BC of no special type may involve the 
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selection of neoplastic clones and/or the acquisition of additional genetic alterations with 
enrichment of mutations affecting certain genes such as FGFR1 (21). 
Prognostic and predictive taxonomies  
Molecular classification of breast cancer 
BC has been classified based on the expression of biomarkers using a variety of 
techniques, concepts and applications. Based on the expression of individual biomarkers, 
BC can be classified into ER positive and ER negative, HER2 positive and HER2 negative. 
Although this appears as a simplified molecular classification system, it remains as the 
most important and informative molecular BC taxonomy to date for clinical management 
in routine practice (15). These two markers with or without addition of other biomarkers; 
namely PgR and Ki67 can be used in combination to provide further important prognostic 
information (22, 23). For instance the response of ER positive HER2 negative tumours to 
hormone therapy is different to ER positive HER2 positive tumours. Despite the predictive 
and prognostic value of hormone receptors and HER2, complex molecular classifications 
based on multiple markers utilising high-throughput techniques have attracted attention as 
a novel method for molecular taxonomy. Molecular classification of BC was initially 
investigated using loss of heterozygosity analysis (LOH), karyotyping and CGH, which 
identified key genomic alterations including losses, gains and amplifications of genomic 
DNA (24-27). This provided the early framework for a molecular classification system that 
stratified BC into distinct classes.  Global gene expression profiling (GEP) studies of BC 
using unsupervised clustering techniques have provided a more established molecular 
classification system and identified distinct clusters or intrinsic subtypes based on the 
quantitative expression of several genes (transcriptome profiles) (28, 29).  Subsequent 
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class discovery studies have also reported an association between molecular intrinsic 
subtypes and patient outcome and that these classes are associated with distinct biological 
pathways making them potential candidates for targeted therapy.  
In the pioneer GEP study by Perou and colleagues in 2000 (28) using the expression of a 
subset (n=496) of differentially expressed genes termed the 'intrinsic' gene set, it was 
demonstrated that BC at the transcriptome level is not a single disease. Despite the fact that 
each individual tumour features a unique GEP related to its specific biological features and 
genetic abnormalities, tumours clustered together to produce distinct reproducible classes 
based on transcriptomic profiles with common overlapping features.  In Perou’s study (28) 
two main clusters were identified and appeared to be related to ER expression. The ER+ 
cluster was enriched with ER, ER-related genes and other genes characteristic of the luminal 
epithelial cells and this class was termed as Luminal to indicate its molecular similarity to 
them. The other major class contained ER-negative tumours and showed three distinct 
subclasses termed HER2-positive, basal-like and normal breast-like.  The HER2 subgroup 
was characterised by overexpression of HER2 and other genes pertaining to the HER2 
amplicon. The basal-like class was largely characterised by the lack of expression of ER and 
HER2 and by positive expression of genes characteristic of basal-like cells of the breast and 
by high proliferative activity. The normal breast-like class displayed a triple-negative 
phenotype but did not cluster with the basal-like centroid and was characterised by 
expression profiles similar to those found in normal breast tissue.  
Subsequent GEP studies indicated that the luminal class, which comprises the majority of 
BC is heterogeneous with respect to the expression of other genes and outcome (30). The 
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Luminal cluster was further stratified into subclasses with at least two distinct subclasses 
reported in many studies; luminal A and luminal B subtypes. Most studies indicated that 
luminal B tumours are associated with a worse prognosis than tumours of the luminal A 
class however, the molecular definition was variable and not reproducible. In general it was 
characterised by ER expression but with higher proliferation rates and/or HER2 expression 
and low or absent PR expression (31).  Other luminal subclasses have been described 
including luminal C (32) and luminal N (33) but the classification into luminal A and B 
remains the most validated sub-classification despite the limitations described above. 
Similar to the luminal class, some studies have classified basal-like tumours into several 
subgroups.  In a previous study of 587 triple negative BC, Lehman and colleagues (34) 
reported six subtypes displaying unique GEP. These include basal-like I, basal-like II, an 
immunomodulatory, a mesenchymal, a mesenchymal stem-like, and a luminal androgen 
receptor (AR) subtype. Other authors have reported four subtypes of triple negative BC 
(luminal AR, mesenchymal, basal-like immune-suppressed, and basal-like immune-
activated) (35) and we have split them into those that have high or low p53 expression (33). 
In addition to their clinical relevance, the molecular intrinsic subtypes showed distinct 
pattern of genomic alterations, emphasising the divergent biological characteristics of 
tumours from these classes. For instance, the luminal A class has the greatest number and 
diversity of significantly mutated genes, with PIK3CA at 45% being the most frequent. 
Luminal B cancers showed mutations affecting both TP53 and PIK3CA. A high proportion 
of tumours in the HER2 class show a high frequency of TP53 and PIK3CA mutations. 
H E R 2 - l u m i n a l - l i k e t u m o u r s h a d h i g h e r e x p r e s s i o n o f g e n e s s u c h 
as GATA3, BCL2 and ESR1 and higher frequency of GATA3 mutations. TP53 mutation is 
most frequent in the basal-like cancers, with most of the significantly mutated genes in 
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luminal tumours being absent. Whilst TP53 mutations are present in the basal-like and 
HER2 tumours, the type of mutation in this gene differs between subtypes (36).  
In recent years several consortia were launched, with researchers from around the world 
collaborating to map the genomes of BC and other cancer. These consortia and other 
research groups started using the ‘multi-omic’ approaches involving different technology 
platforms: genomic DNA copy number arrays, DNA methylation arrays, exome 
sequencing, mRNA arrays, microRNA sequencing and reverse-phase protein arrays to 
develop a more global and integrated ‘picture’ of BC. An example of this genomics-driven 
classification of BC based on an integrative analysis of GEP and genome-wide copy 
number alterations (CNAs) was reported by the Molecular Taxonomy of Breast Cancer 
International Consortium (METABRIC) (37). This study of 2,000 BC reported that the 
number of molecular subtypes is likely to be 10, which are called “integrative clusters” and 
that these subtypes showed distinct clinical behaviour. The Cancer Genome Atlas (TCGA) 
network (38) have analysed 466 BC using five platforms; genomic DNA copy number 
arrays, DNA methylation, exome sequencing, mRNA arrays, microRNA sequencing and 
reverse phase protein arrays. The integrated information across platforms demonstrated the 
existence of four main BC classes, identified two novel protein expression defined 
subgroups related to stroma / microenvironment’s elements and provided key insights into 
previously-defined gene expression subtypes. They have also identified specific signalling 
pathways dominant in each molecular subtype and hypothesised that much of the clinically 
observable heterogeneity and plasticity occurs within, and not across, these major 
molecular subtypes of BC (38).  
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To overcome the problems of fresh tissue, the availability of microarray-based technology, 
cost and assay reproducibility, other techniques such as RT-PCR and IHC coupled with 
tissue microarrays using a smaller set of genes have been introduced to replicate this 
molecular taxonomy and to identify intrinsic subtypes in routine practice. Two main 
approaches have been identified. The first approach was based on identifying a minimum 
gene sets from microarray-based studies and used the minimum set of genes that can 
reliably identify the GEP defined classes. One successful example is the PAM50 
(Prediction of Microarray using 50 classifier genes plus 5 reference genes) classifier (39) 
that categorises BC into four intrinsic subtypes; luminal A, luminal B, HER2-enriched, and 
basal-like. The other surrogate approach to identify intrinsic BC subtypes includes using 
tissue microarrays and IHC utilising a large panel of biologically relevant biomarkers and 
then applying unsupervised clustering techniques to identify molecular classes with and 
without comparison with GEP defined molecular subtypes.  In a previous study we have 
applied 25 IHC biomarkers to 1,076 unselected BC series (40) and identified seven 
molecular classes primarily based on ER and HER2 expression. For a practical use in 
clinical routine practice, the number of biomarkers was reduced for to 10 biomarkers 
which produced comparable classification power (33). As the performance of 
clinicopathological factors varies among the molecular classes, the concept of refining the 
traditional Nottingham Prognostic Index (NPI) that utilises grade, size and lymph node 
status applied equally to BC cases regardless of the molecular features. NPI Plus (NPI+) 
was based on classifying BC into seven distinct molecular classes using the 10 biomarkers 
followed by incorporation of clinicopathological variables to identify distinct prognostic 
groups with each of the classes (33). Using the NPI+ formulae, through incorporating 
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molecular features and clinicopathological parameters, an improved patients’ outcome 
stratification was achieved superior to the traditional NPI (33).   
Although the identification of the intrinsic subtype-based molecular classification of BC 
has attracted attention, and improved our understanding of BC biology and increased hope 
in refinement of BC therapy prediction, their application in routine practice has been less 
successful. Targeted therapy of BC still relies of ER and HER2 regardless of the molecular 
class of the tumour; for instance HER2 positive BC patients are candidates for HER2 
targeted therapy regardless of the intrinsic class whether HER2-enriched or luminal. 
Despite the limited clinical applicability, GEP has opened new avenues for refinement of 
BC molecular prognostication as it has led to the introduction of the molecular multigene 
assays that aim to identify subgroups of BC associated with outcome or specific response 
to therapy (41). This approach is based on identification of a set of genes (gene signature) 
that can be used collectively to identify tumours with specific biological or clinical 
features. The term “genomic signatures” was used to refer to the expression of a set of 
genes in a biologic sample using microarray technology while “metagene” refers to a 
single aggregate measure of the expression of a group of genes that usually show 
coordinated expression in a set of samples and defined by mathematical combination of the 
genes of interest. Most of these multigene assays were used in BC to stratify prognostically 
clinically relevant groups into low and high risk subgroups to guide further treatment. 
Although these molecular classification systems have provided fascinating new insights 
into BC biology and they may have provided more prognostic and better predictive power 
than conventional variables and complement them, we still have a long way to go in terms 
of delivering truly personalised medicine and further work is needed. 
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The first multigene prognostic assay was developed by van't Veer et al. (42) who used a 
class prediction approach utilising a 70-gene set associated with the likelihood of metastasis 
within 5 years. This 70-gene signature was validated in a subsequent study (42) and was 
later commercially marketed as the MammaPrint assay (Agilent, Amsterdam, the 
Netherlands). Other gene signatures have been developed based on prediction of outcome or 
response to specific therapy and used as prognostic and predictive signatures in the clinical 
context used in their development and validation. The most commonly available multigene 
assays include PAM50 risk of recurrence score (Prosigna kit) (43), Oncotype DX assay (44), 
Breast Cancer Index (BCI) (45), EndoPredict (46) and MammaPrint score [4]. Other studies 
have attempted to generate multigene predictors based on a hypothesis derived from in vivo 
or in vitro experiments or on genes characteristic of a biological process and then applied to 
BC samples (47, 48). Examples include genes associated with host immune responses, 
wound healing and other stromal gene signatures that carry prognostic value independent of 
ER status and proliferation and may represent candidate predictive markers for targeted 
therapies (49) (Table 2).   
Despite the minimal overlap between various gene signatures, most of them show clinically 
significant risk stratification particularly in the clinically indeterminate group of ER-
positive, HER2-negative and lymph node-negative or with low nodal burden disease (15, 
50). These multigene prognostic assays are used to stratify BC into distinct prognostic 
groups; high risk and low risk groups with intermediate risk group in some tests. Patients in 
the low risk group can avoid chemotherapy while patients in the high risk group are 
considered as a candidate for chemotherapy.  Current evidence indicates that these 
multigene prognostic assays have limited clinical application in ER negative, HER2 positive 
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and advanced stage tumours as patients with these tumours are typically offered 
chemotherapy(15).    
Molecular classification of special breast tumour types 
Most of the molecular profiling data of BC relate to ductal NST carcinomas which comprise 
approximately 75% of BC and their diagnosis is one of exclusion, when a tumour does not 
fit into a defined special subtype. Comprehensive molecular analysis of ILC (51) which is 
the most common special BC type revealed that besides E-cadherin loss which is the best 
known ILC genetic hallmark there are specific mutations targeting PTEN, TBX3, and 
FOXA1 as ILC enriched features. PTEN loss associated with increased AKT 
phosphorylation appeared to be highest in ILC among all breast cancer subtypes. Global 
gene expression profiling revealed the existence of 3 subtypes of ILC; reactive-like, 
immune-related and proliferative classes (51).  These subtypes showed many significant 
genomic features at the mRNA and protein/phosphoprotein level with 1,277 genes 
differentially expressed between ILC subtypes. However, no difference between these ILC 
subtypes was identified in terms somatic mutations or DNA copy-number alterations. As 
expected the proliferative subtype was associated with the worst outcome whilst the 
reactive-like was associated with the best outcome (51). At the DNA ILC cases were 
significantly enriched for CDH1 mutations and mutations affecting TBX3 and FOXA1. 
GATA3 mutations appeared to be the second most discriminant event between ILC and 
ductal NST carcinoma after CDH1 mutations.  In addition homozygous losses of the PTEN 
locus (10q23) and PTEN mutations were more frequent in ILC (51).  
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Analysis of pure mucinous BC subtype indicated that they show a relatively low level of 
genetic instability and they tend to be homogeneously and preferentially clustered together, 
separately from ductal NST carcinomas. They less frequently harbour gains of 1q and 16p 
and losses of 16q and 22q than grade- and ER-matched ductal NST, and no pure mucinous 
carcinoma displayed concurrent 1q gain and 16q loss, a hallmark genetic feature of low-
grade ductal NST (52). Pure invasive micropapillary carcinoma that has a characteristic 
morphological appearance with a so-called inside-out growth pattern shows specific copy 
number aberrations (53), high cyclin D1 expression, high proliferation rates, and MYC 
(8q24) amplification (54) compared to ER-matched and grade-matched ductal NST. 
Special subtypes that belong to the basal-like subgroup include carcinomas with medullary 
features, as well as metaplastic carcinomas and salivary–gland-like tumours such as adenoid 
cystic carcinoma. Adenoid cystic carcinoma forms an interesting paradox as it sits within 
the basal-like group, which is generally regarded as of poor prognosis, yet its clinical 
behaviour is generally indolent. This underscores the astonishing heterogeneity that can 
occur even within individual intrinsic subtypes.  In a previous study of acinic cell 
carcinomas (ACCs) of the breast using massively parallel sequencing (55), our group 
identified that the most frequently mutated gene is TP53 with a complex patterns of gains 
and losses similar to those of common forms of triple negative BC. Additional somatic 
mutations affecting breast cancer-related genes found in ACCs included PIK3CA, mTOR, 
CTNNB1, BRCA1, ERBB4, ERBB3, INPP4B, and FGFR2. Using NGS approach, our group 
also demonstrated that microglandular adenosis/atypical microglandular adenosis, 
particularly those associated with triple negative BC harboured at least one somatic non-
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synonymous mutation with identical TP53 mutations and similar patterns of gene CNAs in 
microglandular adenosis and in the associated triple negative BC. Clonal shifts in the 
progression from microglandular adenosis to atypical microglandular adenosis and/or to 
triple negative BC were also observed.  On the other hand pure microglandular adenosis 
lacked clonal non-synonymous somatic mutations and displayed limited copy number 
alterations (56). Importantly, these findings, in conjunction with others, underscore the 
significance for microglandular adenosis in clinical diagnosis. In another study of 
infiltrating epitheliosis using the same techniques (57), we demonstrated high prevalence of 
somatic mutations affecting PI3K pathway genes, suggesting that these lesions may be 
neoplastic rather than hyperplastic. The landscape of somatic genetic alterations found in 
infiltrating epitheliosis is similar to that of radial scars/complex sclerosing lesions, 
suggesting that they may represent one end of this spectrum of lesions. 
There is also a strong evidence to indicate that the considerable molecular heterogeneity of 
BC is already present at the pre-invasive level with genomic, transcriptomic and phenotypic 
similarities found between ductal carcinoma in situ (DCIS) and coexisting invasive 
carcinoma (58). Similar to invasive BC, frequent genetic and genomic events have been 
reported in DCIS with several studies provided detailed descriptions of DCIS genomic, 
transcriptomic and proteomic profiling however, to date there are relatively little molecular 
data that can be used to predict the risk of progression to invasive tumour or risk of 
recurrence.  
Next generation sequencing (NGS)  
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The introduction of NGS or massively parallel sequencing (MPS) has revolutionised BC 
genetics and genomics and is expected to assist in utilising for personalised treatment of BC 
patients. Common approaches to NGS include whole-genome sequencing (sequences the 
complete genome of a sample), whole-exome sequencing, targeted exome sequencing 
(target-enrichment methods to capture genes of interest), and hotspot (sequences selected 
regions/regions with recurrent mutations of selected genes of interest) sequencing.  NGS has 
been used to characterise genomic alterations such as copy number changes, insertions/
deletions and mutations, facilitate sequencing at a greater depth (at the base-pair level) 
allowing the identification of subclonal mutations and help distinguishing the “driver” 
mutations that contribute to cancer development from the “passengers” mutations that do 
not appear to play a significant role in disease progression. In addition to providing 
information about the genomic landscape of BC, MPS has confirmed both inter-tumour and 
intra-tumour heterogeneity and showed that each BC is largely unique.   
NGS have indicated that the mutation frequencies found in BC are lower than some other 
cancer such as lung squamous cell carcinoma or bladder urothelial carcinomas but are 
similar to those of ovarian and renal clear cell carcinomas.  Somatic driver point mutations 
and/or copy number changes were identified in at least 40 cancer genes with a maximum of 
6 mutated cancer genes in an individual BC though 28 cases of the 100 BC showed a single 
driver (59). Seven of those 40 cancer genes (TP53, PIK3CA, MYC, ERBB2, FGFR1, 
CCND1 and GATA3) were mutated in >10% of cases and these contributed 58% of driver 
mutations (59).  Overall, BC was found to have a mean of 56.9 (range 5–374) somatic 
mutations per cancer. NGS has also demonstrated spatial and temporal intratumour 
heterogeneity of BC at a level beyond common expectations. Various degrees of intratumour 
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genetic heterogeneity have been demonstrated in BC even in the absence of overt 
histological phenotypic heterogeneity. Triple negative and basal-like tumours tend to have 
greater intra-tumoural heterogeneity than non-basal-like tumours. Mutations in common 
driver genes such as TP53, PIK3CA, and PTEN are usually found in high clonal frequencies 
and several somatic mutations are present in only a fraction of cancer cells. NGS also 
showed that the constellations of somatic mutations found between a primary BC and its 
metastases (temporal heterogeneity) and between distinct areas within the primary tumour 
(spatial heterogeneity) are not identical providing further evidence to indicate that BC 
evolve over the course of the disease. This clonal genetic heterogeneity may explain 
resistance of some BC to selective environmental pressures and therapy. 
An increasing number of molecularly targeted drugs are available in the clinic as approved 
drugs or in the context of clinical trials (http://www.clinicaltrials.gov) and these include 
HER4, EGFR, VEGF, VEGFR, FGFR, KIT, BRAF, mTOR, PDGFR, MEK, TIE2, FLT3, 
SRC, RET, PD1, PDL1 and others (36). These drugs target specific molecular abnormalities, 
including mutated protein kinases and amplified or rearranged genes. BCs that carry any of 
these abnormalities particularly if they harbour the sensitising genomic abnormality is 
expected to respond to the corresponding targeted therapies. For example, the HER2 gene-
amplified BC benefit from HER2-targeted therapies.   
Future perspectives: As a natural extension of the increasing application of the high-
throughput sequencing technology, the list of cancer driver genes is growing, and a 
considerable number of these are potentially targetable.  This may also help to understand 
the mechanisms underlying treatment failure. Furthermore, the identification of targets holds 
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great potential for monitoring clonal evolution in response to treatment and, hence, the early 
detection of treatment failure.  Application of such technologies is already underway is 
expected to result in further refinement of BC prognostication and prediction of response to 
specific therapies. 
In conclusion: Molecular testing has become increasingly important in the prevention, 
diagnosis, and treatment of BC. Despite the enormous amount of work that has been carried 
out to develop and refine BC molecular classification, it is still in evolution. With the 
increasing use of more sophisticated high-throughput techniques such as NGS, large 
amounts of data will continue to emerge, which could potentially lead to identification of 
novel therapeutic targets and allow more precise classification systems that can predict 
outcome and response to therapy.  
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Table 1: Summary of the molecular assays commonly used in breast cancer diagnosis prognosis and therapy 
prediction in clinical practice
ER=oestrogene receptor, PgR= Pprogesterone receptor, IHC= immunohistochemistry, RT-PCR, reverse 
transcription-polymerase chain reaction, FISH, florescence in situ hybridisation.
Assay Analyte Method Applications 
Diagnostic assays
Diagnostic biomarker 
panels
Proteins IHC IHC biomarkers can be used for diagnosis of 
histologically challenging breast lesions, 
differentiate between mammary and non-
mammary tumours, and between metaplastic 
spindle cell carcinomas from other benign 
spindle cell lesions. IHC can also be used to 
differentiate ADH/low grade DCIS from 
hyperplasia, in situ from invasive carcinomas 
and ductal from lobular tumours. 
Chromosomal 
translocation and fusion 
genes
Tumour 
DNA
FISH or RT-PCR Specific translocations are reported to be 
specific to certain breast lesions such as 
secretory and mucoepidermoid carcinoma of 
the breast 
Predictive and prognostic 
assays
ER and PgR expression Protein IHC Prediction of hormone therapy response, 
prognostic and diagnostic markers. Also provide 
some information on response to 
chemotherapy; ER- tumours respond better 
than ER+ tumours
HER2 status Protein IHC Protein overexpression and/or gene 
amplification predict response to antiHER2 
targeted therapy. It also provides prognostic 
information and can be used to help in 
diagnosis (ie Paget’s disease)  
Tumour 
DNA (HER2 
gene copy 
number)
ISH; FISH, 
CISH, DDISH
Germ line testing Non tumour 
DNA 
DNA 
sequencing
BRCA-germ line positivity predicts good 
response to PARP inhibitors and other synthetic 
lethality approach and to some extent 
chemotherapy. Identify genetic predisposition 
and indication for counsel patients and relatives 
in addition to guiding screening
Ki67 labelling index Protein IHC It used in some centres to assess proliferation 
status as a prognostic variable. Also used as a 
component of some prognostic tools such as 
PREDICT. May be useful in poorly fixed 
tumours and in grade 2 cancers
Multigene assays Tumour 
RNA
RT-PCR, 
Expression 
microarrays and 
nCounter 
technology 
platform
Prognostic in ER+, HER2- breast cancer and 
mainly used in patients with lymph node 
negative ER+ HER2- tumours treated with 
hormone therapy to determine the risk and 
benefits of using chemotherapy. Currently not 
recommended in metastatic, locally advanced 
or advanced stage tumours and have limited 
prognostic value in ER- and HER2 positive 
tumours
Protein IHC
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Table 2: Summary of prognostic multigene assays that are currently available for early stage invasive breast 
cancer
Test Name Component 
gene(s)
Intended Clinical Utility Biological 
Material/
Technology
Classificati
on
MammaPrint/
Amsterdam 
Signature (42)
70 genes (first 
prognostic gene 
signature to be 
identified)
Node negative ER+ or ER- 
Estimates the recurrence 
risk. 
Test may extend to node 
positive patients
Fresh or 
FFPE, 
Microarray
2 
categories: 
low risk and 
high risk
Oncotype DX 
(recurrence 
score) (44)
21 genes (16 
cancer-related 
and 5 controls)
 ER+, HER2-, node-
negative BC.  
Predicts the likelihood of 
chemotherapy benefit as 
well as recurrence in 
hormone therapy treated 
patients. 
Test may extend to node-
positive patients
FFPE, RT-
PCR
3 
categories: 
low risk 
(RS<18), 
intermediat
e risk (RS 
18–30), or 
high risk 
(RS>31)
EndoPredict 
(60)
11 genes (8 
cancer-related 
and 3 controls)
Predicts distant and late 
recurrences in ER+ / 
HER2- node negative and 
positive patients treated 
with endocrine therapy 
alone
FFPE, RT-
PCR
Two 
categories. 
Can be 
combined 
with tumour 
size and 
nodal status 
to produce 
clinical 
score 
(EPclin) 
Prosigna 
(PAM50) Kit 
(risk of 
recurrence 
assay; ROR) 
(43)
50 genes (used 
in the PAM50 
molecular 
classification 
assay) and 5 
control genes
ER+ node negative and 
positive treated with 
hormone therapy. 
Evaluates distant 
recurrence-free survival 
at 10 years 
FFPE, RT-
PCR and by 
the 
nCounter 
Dx analysis 
system
3 
categories: 
low, 
intermediat
e and high 
risk
Breast Cancer 
Index (BCI) (17)
A combination 
of MGI (5 
genes) and the 
2 gene ratio 
(H/I) 
(HOXB13:IL17B
R)
Risk of distant 
recurrence in ER+ node 
negative BC. 
Risk of late distant 
metastasis and benefit 
from extended (>5 years) 
endocrine therapy
FFPE, RT-
PCR
Two 
categories
The Rotterdam 
Signature (61)
76 genes (60 
genes for ER+ 
and 16 genes 
for ER-patients)
Node negative patients. 
Predict recurrence in ER+ 
treated with tamoxifen
Fresh 
tissue, 
Microarray
Two 
categories
BluePrint® 
Molecular 
Signature
80-gene profile Classifies tumours into 
intrinsic subtypes to 
suggest the potential 
effect of adjuvant 
therapy
FFPE, 
Microarray
  28
FFPE, Formalin-fixed paraffin-embedded, ER, oestrogen receptor; PgR, progesterone receptor; RT-PCR, 
reverse transcription-polymerase chain reaction, FISH, florescence in situ hybridisation.  
IHC and in situ hybridisation-based assays 
IHC4 score 4 genes (ER, 
PgR, Ki67 and 
HER2
ER+ patients treated with 
hormone therapy
FFPE and 
IHC
Insight Dx 
Mammostrat 
Plus
9 genes (As 
above plus ER, 
PgR, KI67 and 
HER2)
 As above, plus hormone 
receptor/HER2 status
FFPE, 
additional 
genes 
evaluated 
by IHC and 
FISH
2 categories
Assays based on signatures characteristic of a biological process
Wound-response 
signature(62)
442 genes Node negative and 
positive
Fresh, 
Microarray
2 categories
Immune signatures 14 genes 
related to 
immune 
function
Predictive for relapse in 
trastuzumab-treated HER2+ 
patients
2 categories
Invasiveness Gene 
Signature (IGS)
186 genes Predict 10-year distant 
metastasis free survival in 
node negative patients
Fresh, 
Microarray
2 categories
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